Ipsen Announces At American Society of Clinical Oncology GI That ELECT&#0174 Clinical Trial Of Somatuline&#0174 In The Control Of Symptoms In GEP-NET1 Patients With Carcinoid Syndrome Met Its Primary Endpoint

Published: Jan 17, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced that the results of the ELECT® phase III clinical study with Somatuline® Autogel® / Somatuline® Depot® (lanreotide) Injection (hereafter referred to as Somatuline®) will be presented on Friday 17 January 2014 at the Gastrointestinal Cancers Symposium, San Francisco, CA, USA.

Help employers find you! Check out all the jobs and post your resume.

Back to news